The research has been led by Milan’s Istituto San Raffaele, with the Istituto Telethon of gene therapy and the Università Vita e Salute.
Also working on the project were the universities of Turin and Verona, the French Institute for Health and Medical Research (INSERM), the Biopolis research centre in Singapore and the University of Shanghai.
Favouring the growth of this form of tumour, which is still highly lethal, the ductal adenocarcinoma of the pancreas forms a special alliance between particular types of immune cells called IL-1beta+ macrophages, and some very aggressive tumour cells, known for being linked to inflammation.
“It’s a sort of self-feeding vicious circle,” said research leader Renato Ostuni, head of the Innate Immune System Genomics Lab at the Istituto Sr-Tiget and associate professor at the Università Vita-Salute San Raffaele.
“The macrophages make the tumour cells more aggressive, and the tumour cells reprogramme the macrophages capable of favouring inflammation, and the progression of the disease.”
The authors of the research said, “We have taken a good step forward in the understanding of the biological processes underlying the disease.”
“However, we are at a stage of pre-clinical research, still distant from application in patients.
“The coming years will be essential to identify the potentialities and the most appropriate modalities to act on this new therapeutic target.”
The project was backed by Fondazione Airc, Italy’s cancer research foundation, the European Research Council, and the Italian health ministry.
ANSA
